RESPIRATORY INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS, PRIMARY AND SECONDARY AFS BEFORE AND AFTER VACCINATION WITH 23-VALENT POLYSACCHARIDE PNEUMOCOCCAL VACCINE

被引：0
|
作者：
Koilubaeva, G. [1 ]
Tarasova, G. [2 ]
Belov, B. [2 ]
Bolotbekova, A. [1 ]
Syunbai, K. G. [1 ]
Turatbekova, A. [1 ]
机构：
[1] Rheumatol, 3 Togolok Moldo St, Bishkek, Kyrgyzstan
[2] Rheumatol, Kashirskoye Shosse 34, Moscow, Russia
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷
关键词：
Vaccination/immunization;
D O I：
10.1136/annrheumdis-2023-eular.942
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB1668
引用
收藏
页码：2070 / 2071
页数：2
相关论文
共 50 条
  • [41] ANTIBODY-RESPONSE AND PERSISTENCE AFTER VACCINATION OF OLDER MEN WITH 23-VALENT PNEUMOCOCCAL VACCINE
    ROWLAND, J
    MUSHER, D
    MUFSON, M
    GROOVER, J
    WATSON, D
    CLINICAL RESEARCH, 1991, 39 (04): : A843 - A843
  • [42] Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Frenck, Robert W.
    Treanor, John
    Jansen, Kathrin U.
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3594 - 3602
  • [43] Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
    Schmoele-Thoma, Beate
    van Cleeff, Martin
    Greenberg, Richard N.
    Gurtman, Alejandra
    Jones, Thomas R.
    Sundaraiyer, Vani
    Gruber, William C.
    Scott, Daniel A.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (03) : 575 - 583
  • [44] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults
    Jackson, Lisa A.
    Gurtman, Alejandra
    van Cleeff, Martin
    Jansen, Kathrin U.
    Jayawardene, Deepthi
    Devlin, Carmel
    Scott, Daniel A.
    Emini, Emilio A.
    Gruber, William C.
    Schmoele-Thoma, Beate
    VACCINE, 2013, 31 (35) : 3577 - 3584
  • [45] Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previously immunised with 23-valent pneumococcal polysaccharide vaccine
    Rezende, Rodrigo Poubel
    Coelho Andrade, Luis Eduardo
    Klumb, Evandro Mendes
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (06) : 854 - +
  • [46] Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to prevent secondary bacterial infections related to pandemic influenza in Brazil
    O'Brien, M.
    Dhankhar, P.
    Grabenstein, J.
    Dasbach, E. J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E449 - E450
  • [47] Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster
    Russell, F. M.
    Carapetis, J. R.
    Satzke, C.
    Tikoduadua, L.
    Waqatakirewa, L.
    Chandra, R.
    Seduadua, A.
    Oftadeh, S.
    Cheung, Y. B.
    Gilbert, G. L.
    Mulholland, E. K.
    CLINICAL AND VACCINE IMMUNOLOGY, 2010, 17 (12) : 1970 - 1976
  • [48] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    VACCINE, 2024, 42 (13) : 3190 - 3196
  • [49] Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly
    Won, Heehyun
    Kim, Jeong Ah
    Jeong, Na-Young
    Choi, Nam-Kyong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 24 - 25
  • [50] Does 23-Valent Pneumococcal Polysaccharide Vaccination Decrease All-Cause Mortality?
    Rezahosseini, Omid
    Eiberg, Mads Frederik
    Weinberger, Daniel M.
    Harboe, Zitta Barrella
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (11):
12345